Trials / Completed
CompletedNCT04836520
SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.
Single-arm, Single-center, PhaseⅡ Clinical Study of SHR6390 Combined With Anastrozole for Preoperative Treatment of Hormone Receptor Positive and HER2 Negative Early or Locally Advanced Breast Cancer.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to assess effect of SHR6390 combined with anastrozole on proliferation of HR-positive HER2-negative breast cancer tumor cells before surgery.
Detailed description
This is a single-arm, single-center, open-label Phase II clinical study. The purpose of this study was to evaluate the effect of SHR6390 combined with anastrozole on the proliferative activity of HR-positive HER2-negative breast cancer tumor cells before surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR6390+anatrozole | SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway. |
Timeline
- Start date
- 2021-08-02
- Primary completion
- 2023-02-28
- Completion
- 2023-03-31
- First posted
- 2021-04-08
- Last updated
- 2023-04-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04836520. Inclusion in this directory is not an endorsement.